Isis Pharmaceuticals has earned a $2.15 million milestone payment from Biogen for advancing the ongoing Phase III study (CHERISH) evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA). To date, Isis has received more than $120 million in payments from Biogen related to the development of ISIS-SMNRx.   The Phase III study of ISIS-SMNRx, will evaluate the efficacy and safety of 12 mg doses of ISIS-SMNRx with a primary endpoint of a change in the Hammersmith Functional Motor Scale-...